Navigation Links
STALLERGENES: 2008: Strong Performance
Date:3/24/2009

re remarkable that it was achieved against the background of a significant investment phase relating to the rollout of the Stalair(R) program (the Stalair(R) program is the new umbrella marketing name of the range of sublingual desensitization tablets). Net R&D expenditure thus increased by 26% and represent 17.5% of sales.

Net profit increased by 17% to EUR 19.0 million and represented an 11.1% net profit margin.

The financial independence of the Group was maintained. EBITDA (gross cash surplus) grew by 14% to EUR 34.3 million, which was largely sufficient to cover investments (EUR 18.3 million), while at the same time generating, for the eighth year in a row, a positive free cash flow of EUR 4.7 million.

Stallergenes strengthened its already sound balance sheet and as a result looks forward to its expansion with confidence. The net financial debt further declined to EUR 9.6 million and only represents 0.3 times EBITDA and 12% of equity.

The Group's 2008 consolidated financial statements are available from the Group's website: http://www.stallergenes.com .

2009 outlook

As regards the Stalair(R) program, five major phase II/III clinical study results are pending. Three of these are "pivotal" studies that will lead to registrations.

The Group remains prudent to date on providing a sales guidance and expects sales growth of between 8% and 10%.

Investments will remain at a high level, without however calling into question Stallergenes' objective of maintaining an operating profitability in excess of 15% of sales and a positive free cash flow.

Significant recent transactions and events

The marketing authorization of Oralair(R) (grass pollen tablets) in its paediatric indication was delivered on 19 January 2009 by the German agency. Oralair(R) is thus mark
'/>"/>

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
2. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
3. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
4. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
5. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
6. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
7. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
8. Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value
9. BIO 2008: Germany on Cutting Edge in Biomanufacturing
10. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
11. Commencement 2008: Student innovation could improve data storage, magnetic sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. (PRWEB) January 15, 2014 Cynvenio, ... and management through the genomic analysis of tumor cells ... Therapy Finder™, a web-based cancer decision support application powered ... option with Cynvenio’s ClearID™ genomic test, Therapy Finder will ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... 15, 2014 Freeslate, Inc ., ... announced that Lupin Limited, one of India’s top five ... Protégé PharmD System for high throughput solid form ... focused on a wide range of quality, affordable generic ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Bioactive Small Molecules through ... ... today announced the addition of 1,300 bioactive small molecules to,its ... provides expanded data on the functional relationship between,bioactive small molecules ...
... Enable Healthcare ... Providers Access to PET Technology, HOFFMAN ... today announced its first molecular imaging,biomarker production facility in ... in and around Chennai to access the,positron emission tomography-computed ...
... Burke, MD, Executive Vice,President and Physician-in-Chief at The ... elected the 40th President of the Society of,Gynecologic ... March 9-12, 2008 in Tampa, Florida., Dr. ... Tulane,University in New Orleans, Louisiana. He served both ...
Cached Biology Technology:Sigma-Aldrich Partners With Sunset Molecular Discovery to Expand Your Favorite Gene Search Tool 2Siemens to Launch PETNET Services in India 2Siemens to Launch PETNET Services in India 3Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 2Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists 3
(Date:4/23/2014)... by a University of Exeter researcher has shed light ... camels thriving in Australia,s remote outback have become reviled ... Sarah Crowley, of the Environment and Sustainability Institute at ... of the camel in Australia, from their historic role ... current status as unwelcome "invader." , The deserts of ...
(Date:4/23/2014)... one can argue that if we were to follow a ... we canthen we can solve the climate problem without doing ... climate researchers, in the current issue of Bulletin of ... significant action on climate change now makes it more likely ... Wigley explains in an exclusive Bulletin interview. ...
(Date:4/22/2014)... 2014 Scientists from the Florida campus of The ... that plays a critical but previously unknown role in ... showed a novel role for a protein known as ... eLife , a publisher supported by the Howard ... Wellcome Trust. , "This is a critical building block ...
Breaking Biology News(10 mins):How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Is nuclear power the only way to avoid geoengineering? 2Scientists identify critical new protein complex involved in learning and memory 2
... 5, 2013 What can the U.S. military learn from ... enemies, according to researchers at UC Irvine,s Henry Samueli School ... in Advanced Materials , they have created a biomimetic ... squids or your everyday calamari. Led by Alon Gorodetsky, ...
... announced today in Milan by the Chairman of the ... President of the Balzan "Prize" Foundation, Ambassador Bruno Bottai, ... profiles of the winners and the citations (the Prizes ... held in Bern on November 15) were presented by ...
... , September 9, 2013 Cytos Biotechnology Ltd ... trial with CYT003, a first-in-class immune modulator in clinical development ... analysis of data published in the March issue of ... presented today at the European Respiratory Society Annual Congress in ...
Cached Biology News:UCI researchers fabricate new camouflage coating from squid protein 22013 Balzan prizewinners announced today in press conference in Milan 22013 Balzan prizewinners announced today in press conference in Milan 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 2Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 3Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 4Cytos Biotechnology Presents Additional Results From Phase 2a Study of CYT003 for the Treatment of Allergic Asthma 5
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Acetyl-Histone H2B (Lys20) Antibody...
Biology Products: